As of 2024-12-11, the Intrinsic Value of Tissue Regenix Group PLC (TRX.L) is
14.66 GBP. This TRX.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 57.00 GBP, the upside of Tissue Regenix Group PLC is
-74.30%.
The range of the Intrinsic Value is 5.08 - 47.69 GBP
14.66 GBP
Intrinsic Value
TRX.L Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
5.08 - 47.69 |
14.66 |
-74.3% |
| DCF (Growth 10y) |
49.26 - 214.71 |
86.34 |
51.5% |
| DCF (EBITDA 5y) |
71.72 - 124.91 |
97.34 |
70.8% |
| DCF (EBITDA 10y) |
123.07 - 237.13 |
174.52 |
206.2% |
| Fair Value |
-35.56 - -35.56 |
-35.56 |
-162.38% |
| P/E |
(33.54) - (38.76) |
(35.63) |
-162.5% |
| EV/EBITDA |
28.28 - 59.70 |
46.96 |
-17.6% |
| EPV |
(40.65) - (55.36) |
(48.00) |
-184.2% |
| DDM - Stable |
(19.32) - (113.12) |
(66.22) |
-216.2% |
| DDM - Multi |
33.04 - 151.88 |
54.45 |
-4.5% |
TRX.L Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
40.60 |
| Beta |
-0.30 |
| Outstanding shares (mil) |
0.71 |
| Enterprise Value (mil) |
47.61 |
| Market risk premium |
5.98% |
| Cost of Equity |
7.41% |
| Cost of Debt |
16.53% |
| WACC |
8.94% |